MICROBIOLOGÍA, ENFERMEDADES INFECCIOSAS, ANTIMICROBIANOS Y TERAPIA GÉNICA
Hospital Universitario Puerta del Mar
Cádiz, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta del Mar (11)
2022
-
Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry
Clinical Microbiology and Infection, Vol. 28, Núm. 2, pp. 260-266
-
Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project
Microbiology spectrum, Vol. 10, Núm. 4, pp. e0005122
2021
-
Azole and amphotericin B MIC values against aspergillus fumigatus: High agreement between spectrophotometric and visual readings using the EUCAST EDef 9.3.2 procedure
Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 1
-
Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain
Clinical Microbiology and Infection, Vol. 27, Núm. 8, pp. 1170.e1-1170.e7
2020
-
The value of the continuous genotyping of multi-drug resistant tuberculosis over 20 years in Spain
Scientific Reports, Vol. 10, Núm. 1
2019
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
BMC Infectious Diseases, Vol. 19, Núm. 1
2017
-
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
-
Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277
2007
-
Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: Second National Study (2003)
Revista Espanola de Quimioterapia, Vol. 20, Núm. 2, pp. 222-229
-
Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate
Alimentary Pharmacology and Therapeutics, Vol. 25, Núm. 8, pp. 899-906